Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 3, 2014, Pages 1284-1293

  Oliva, Alessandra ^a,b   Furustrand Tafin, Ulrika ^a   Maiolo, Elena Maryka ^a,b   Jeddari, Safaa ^a   Bétrisey, Bertrand ^a   Trampuza, Andrej ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; DAPTOMYCIN; FOSFOMYCIN; GENTAMICIN; LINEZOLID; RIFAMPICIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BIOFILM; COLONY FORMING UNIT; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; EXPERIMENTAL INFECTION; FOREIGN BODY INFECTION; IN VITRO STUDY; MALE; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ACETAMIDES; AMPICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL ADHESION; BIOFILMS; CALORIMETRY; DAPTOMYCIN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENTEROCOCCUS FAECALIS; FOREIGN BODIES; FOSFOMYCIN; GENTAMICINS; GRAM-POSITIVE BACTERIAL INFECTIONS; GUINEA PIGS; MALE; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; RIFAMPIN; VANCOMYCIN;

EID: 84896837944     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02583-12     Document Type: Article

References (57)

1. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322. (Pubitemid 29289651)
2. Stewart PS, Costerton JW. 2001. Antibiotic resistance of bacteria in biofilms. Lancet 358:135-138. http://dx.doi.org/10.1016/S0140-6736(01)05321-1. (Pubitemid 32709857)
3. Trampuz A, Widmer AF. 2006. Infections associated with orthopedic implants. Curr. Opin. Infect. Dis. 19:349-356. http://dx.doi.org/10.1097/01.qco. 0000235161.85925.e8. (Pubitemid 43982507)
4. Calfee DP. 2012. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, and other Gram-positives in healthcare. Curr. Opin. Infect. Dis. 25:385-394. http://dx.doi.org/10.1097/QCO.0b0133283553441.
5. Arias CA, Murray BE. 2012. The rise of the Enterococcus: beyond vancomycin resistance. Nat. Rev. Microbiol. 10:266-278. http://dx.doi.org/10. 1038/nrmicro2761.
6. Mohamed JA, Huang DB. 2007. Biofilm formation by enterococci. J. Med. Microbiol. 56:1581-1588. http://dx.doi.org/10.1099/jmm.0.47331-0. (Pubitemid 350276505)
7. Sava IG, Heikens E, Huebner J. 2010. Pathogenesis and immunity in enterococcal infections. Clin. Microbiol. Infect. 16:533-540. http://dx.doi.org/10.1111/j.1469-0691.2010.03213.x.
8. Zimmerli W, Trampuz A, Ochsner PE. 2004. Prosthetic-joint infections. N. Engl. J. Med. 351:1645-1654. http://dx.doi.org/10.1056/NEJMra040181.
9. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. 1998. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 279:1537-1541. (Pubitemid 28233008)
10. Furustrand Tafin U, Majic I, Zalila Belkhodja C, Betrisey B, Corvec S, Zimmerli W, Trampuz A. 2011. Gentamicin improves the activities of daptomycin and vancomycin against Enterococcus faecalis in vitro and in an experimental foreign-body infection model. Antimicrob. Agents Chemother. 55:4821-4827. http://dx.doi.org/10.1128/AAC.00141-11.
11. Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE. 2009. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin. Invest. Drugs 18:921-944. http://dx.doi.org/10.1571/13543780902967624.
12. Michalopoulos AS, Livaditis IG, Gougoutas V. 2011. The revival of fosfomycin. Int. J. Infect. Dis. 15:e732- e739. http://dx.doi.org/10.1016/j. ijid.2011.07.007.
13. Raz R. 2012. Fosfomycin: an old-new antibiotic. Clin. Microbiol. Infect. 18:4-7. http://dx.doi.org/10.1111/j.1469-0691.2011.03636.x.
14. Poeppl W, Tobudic S, Lingscheid T, Plasenzotti R, Kozakowski N, Lagler H, Georgopoulos A, Burgmann H. 2011. Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model. Antimicrob. Agents Chemother. 55:4999-5003. http://dx.doi.org/10. 1128/AAC.00584-11.
15. Marchese A, Bozzolasco M, Gualco L, Debbia EA, Schito GC, Schito AM. 2003. Effect of fosfomycin alone and in combination with N-acetylcysteine on E. coli biofilms. Int. J. Antimicrob. Agents 22(Suppl 2):95-100. http://dx.doi.org/10.1016/S0924-8579(03)00232-2.
16. Baldoni D, Haschke M, Rajacic Z, Zimmerli W, Trampuz A. 2009. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob. Agents Chemother. 53:1142-1148. http://dx.doi.org/10.1128/AAC.00775-08.
17. John AK, Baldoni D, Haschke M, Rentsch K, Schaerli P, Zimmerli W, Trampuz A. 2009. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob. Agents Chemother. 53:2719-2724. http://dx.doi.org/10.1128/ AAC.00047-09.
18. Trampuz A, Murphy CK, Rothstein DM, Widmer AF, Landmann R, Zimmerli W. 2007. Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. Antimicrob. Agents Chemother. 51:2540-2545. http://dx.doi.org/10.1128/AAC.00120-07. (Pubitemid 47047334)
19. Zimmerli W, Frei R, Widmer AF, Rajacic Z. 1994. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J. Antimicrob. Chemother. 33:959-967. (Pubitemid 24170895)
20. Blaser J, Vergeres P, Widmer AF, Zimmerli W. 1995. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob. Agents Chemother. 39:1134-1139.
21. Bridier A, Dubois-Brissonnet F, Boubetra A, Thomas V, Briandet R. 2010. The biofilm architecture of sixty opportunistic pathogens deciphered using a high throughput CLSM method. J. Microbiol. Methods 82:64-70. http://dx.doi.org/10.1016/j.mimet.2010.04.006.
22. CLSI. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, seventh ed. Document M7-A7. CLSI, Wayne, PA.
23. Braissant O, Wirz D, Gopfert B, Daniels AU. 2010. Use of isothermal microcalorimetry to monitor microbial activities. FEMS Microbiol. Lett. 303:1-8. http://dx.doi.org/10.1111/j.1574-6968.01819.x.
24. Trampuz A, Salzmann S, Antheaume J, Daniels AU. 2007. Microcalorimetry: a novel method for detection of microbial contamination in platelet products. Transfusion 47:1643-1650. http://dx.doi.org/10.1111/j.1537-2995.2007.01336.x. (Pubitemid 47300610)
25. Trampuz A, Steinhuber A, Wittwer M, Leib SL. 2007. Rapid diagnosis of experimental meningitis by bacterial heat production in cerebrospinal fluid. BMC Infect. Dis. 7:116. http://dx.doi.org/10.1186/1471-2334-7-116.
26. von Ah U, Wirz D, Daniels AU. 2009. Isothermal micro calorimetry. A new method for MIC determinations: results for 12 antibiotics and reference strains of E. coli and S. aureus. BMC Microbiol. 9:106. http://dx.doi.org/10.1186/1471- 2180-9-106.
27. Zimmerli W, Waldvogel FA, Vaudaux P, Nydegger UE. 1982. Pathogenesis of foreign body infection: description and characteristics of an animal model. J. Infect. Dis. 146:487-497. (Pubitemid 12004448)
28. Poeppl W, Tobudic S, Lingscheid T, Plasenzotti R, Kozakowski N, Georgopoulos A, Burgmann H. 2011. Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 55:931-933. http://dx.doi.org/10.1128/AAC.00881-10.
29. Pachon-Ibanez ME, Ribes S, Dominguez MA, Fernandez R, Tubau F, Ariza J, Gudiol F, Cabellos C. 2011. Efficacy of fosfomycin and its combination with linezolid, vancomycin and imipenem in an experimental peritonitis model caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin. Eur. J. Clin. Microbiol. Infect. Dis. 30:89-95. http://dx.doi.org/10.1007/ s10096-010-1058-0.
30. Ribes S, Taberner F, Domenech A, Cabellos C, Tubau F, Linares J, Viladrich PF, Gudiol F. 2006. Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. 57:931-936. http://dx.doi.org/10.1093/jac/dkl047.
31. Amyes SG. 2007. Enterococci and streptococci. Int. J. Antimicrob. Agents 29(Suppl 3):S43-S52. http://dx.doi.org/10.1016/S0924-8579(07)72177-5. (Pubitemid 47064504)
32. Courvalin P. 2006. Vancomycin resistance in gram-positive cocci. Clin. Infect. Dis. 42(Suppl 1):S25-S34. http://dx.doi.org/10.1086/491711. (Pubitemid 41832062)
33. Popovic M, Steinort D, Pillai S, Joukhadar C. 2010. Fosfomycin: an old, new friend? Eur. J. Clin. Microbiol. Infect. Dis. 29:127-142. http://dx.doi.org/10.1007/s10096-009-0833-2.
34. Alos JI, Garcia-Pena P, Tamayo J. 2007. Biological cost associated with fosfomycin resistance in Escherichia coli isolates from urinary tract infections. Rev. Esp. Quimioter. 20:211-215. (In Spanish.) http://www.seq.es/ seq/0214-3429/20/2/211/pdf.
35. Marchese A, Gualco L, Debbia EA, Schito GC, Schito AM. 2003. In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int. J. Antimicrob. Agents 22(Suppl 2):53-59. http://dx.doi.org/10.1016/S0924-8579(03)00230-9.
36. Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. 2003. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob. Agents Chemother. 47:2850-2858. http://dx.doi.org/10.1128/AAC.47.9. 2850-2858.2003. (Pubitemid 37040258)
37. Fontana R, Boaretti M, Grossato A, Tonin EA, Lleò MM, Satta G. 1990. Paradoxical response of Enterococcus faecalis to the bactericidal activity of penicillin is associated with reduced activity of one autolysin. Antimicrob. Agents Chemother. 34:314-320. (Pubitemid 20046887)
38. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. 1999. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 37:1771-1776. (Pubitemid 29235221)
39. Mikuniya T, Kato Y, Ida T, Maebashi K, Monden K, Kariyama R, Kumon H. 2007. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model. J. Infect. Chemother. 13:285-290. http://dx.doi.org/10.1007/s10156-007-0534-7. (Pubitemid 350059914)
40. Grif K, Dierich MP, Pfaller K, Miglioli PA, Allerberger F. 2001. In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J. Antimicrob. Chemother. 48:209-217. http://dx.doi.org/10.1093/jac. 48.2.209. (Pubitemid 32755281)
41. Corvec S, Furustrand Tafin U, Betrisey B, Borens O, Trampuz A. 2013. Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum β-lactamase-producing Escherichia coli in a foreign-body infection model. Antimicrob. Agents Chemother. 57:1421-1427. http://dx.doi.org/10.1128/AAC.01718-12.
42. Garrigos C, Murillo O, Lora-Tamayo J, Verdaguer R, Tubau F, Cabellos C, Cabo J, Ariza J. 2013. Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 57:606-610. http://dx.doi.org/10.1128/AAC.01570-12.
43. Morikawa K, Nonaka M, Torii I, Morikawa S. 2003. Modulatory effect of fosfomycin on acute inflammation in the rat air pouch model. Int. J. Antimicrob. Agents 21:334-339. http://dx.doi.org/10.1016/S0924-8579(02)00358-8. (Pubitemid 36397966)
44. Vergidis P, Rouse MS, Euba G, Karau MJ, Schmidt SM, Mandrekar JN, Steckelberg JM, Patel R. 2011. Treatment with linezolid or vancomycin in combination with rifampin is effective in an animal model of methicillin-resistant Staphylococcus aureus foreign body osteomyelitis. Antimicrob. Agents Chemother. 55:1182-1186. http://dx.doi.org/10.1128/AAC.00740- 10.
45. Widmer AF, Gaechter A, Ochsner PE, Zimmerli W. 1992. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin. Infect. Dis. 14:1251-1253.
46. Holmberg A, Morgelin M, Rasmussen M. 2012. Effectiveness of ciprofloxacin or linezolid in combination with rifampicin against Enterococcus faecalis in biofilms. J. Antimicrob. Chemother. 67:433-439. http://dx.doi.org/10.1093/jac/ dkr477.
47. Minardi D, Cirioni O, Ghiselli R, Silvestri C, Mocchegiani F, Gabrielli E, d'Anzeo G, Conti A, Orlando F, Rimini M, Brescini L, Guerrieri M, Giacometti A, Muzzonigro G. 2012. Efficacy of tigecycline and rifampin alone and in combination against Enterococcus faecalis biofilm infection in a rat model of ureteral stent. J. Surg. Res. 176:1-6. http://dx.doi.org/10.1016/j.jss.2011.05. 002.
48. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. 2006. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob. Agents Chemother. 50:3245-3249. http://dx.doi.org/10.1128/AAC.00247-06. (Pubitemid 44527494)
49. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. 2003. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 47:1318-1323. http://dx.doi.org/10.1128/AAC.47.4.1318-1323.2003. (Pubitemid 36368592)
50. Wise R, Gee T, Andrews JM, Dvorchik B, Marshall G. 2002. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob. Agents Chemother. 46:31-33. http://dx.doi.org/10.1128/AAC.46.1.31- 33.2002. (Pubitemid 34031598)
51. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak M, Jr, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 52:285-292. http://dx.doi.org/10.1093/cid/cir034.
52. Hall AD, Steed ME, Arias CA, Murray BE, Rybak MJ. 2012. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 56:3174-3180. http://dx.doi.org/10.1128/AAC.06439-11.
53. Arias CA, Torres HA, Singh KV, Panesso D, Moore J, Wanger A, Murray BE. 2007. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin. Infect. Dis. 45:1343-1346. http://dx.doi.org/10.1086/522656. (Pubitemid 351411911)
54. Long JK, Choueiri TK, Hall GS, Avery RK, Sekeres MA. 2005. Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin. Proc. 80:1215-1216. http://dx.doi.org/10.4065/80.9.1215. (Pubitemid 41233359)
55. Munoz-Price LS, Lolans K, Quinn JP. 2005. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin. Infect. Dis. 41:565-566. http://dx.doi.org/10.1086/432121. (Pubitemid 41099656)
56. Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. 2007. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J. Infect. 54:567-571. http://dx.doi.org/10. 1016/j.jinf.2006.11.007. (Pubitemid 46731225)
57. Souli M, Galani I, Boukovalas S, Gourgoulis MG, Chryssouli Z, Kanellakopoulou K, Panagea T, Giamarellou H. 2011. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob. Agents Chemother. 55:2395-2397. http://dx.doi.org/10.1128/AAC.01086-10.